In another study, treatment with the BACE inhibitor RO5508887 reduced amyloid plaque load and formation in an AD transgenic mouse model and combined treatment with an anti-Aβ antibody (gantenerumab) further enhanced these effects (Jacobsen et al., 2014), however the impact on cognition was not investigated. Here, BACE1 is linked to Alzheimer disease.